ReviewCurrent neuropharmacology2016
Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment.
Review in Current neuropharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 68 citations in OpenAlex.
- Association between Depression and Risk of Colorectal Cancer and Polyps: A Prospective Cohort Study from the Nurses' Health Study II.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- The effect of sertraline on depressive symptoms and serum inflammatory factors in adolescent with depression.Psychopharmacology · 2025Article
- Repurposing of nervous system drugs for cancer treatment: recent advances, challenges, and future perspectives.Discover oncology · 2025Review
- Combination Therapy Against Mood and Anxiety Disorders: Association Between Efficacy and White Blood Cell Count.Neuropsychiatric disease and treatment · 2025Article
- Transdiagnostic Associations between Anger Hostility and Chemokine Interferon-gamma Inducible Protein 10.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Zhi Zi Chi decoction (Gardeniae fructus and semen Sojae Praeparatum) attenuates anxious depression via modulating microbiota-gut-brain axis in corticosterone combined with chronic restraint stress-induced mice.CNS neuroscience & therapeutics · 2024Article
- Baseline gut microbiota profiles affect treatment response in patients with depression.Frontiers in microbiology · 2024Review
- Neuroinflammation modifies the relationship between stress and perivascular spaces in an elderly population with different levels of cognitive impairment.Frontiers in cellular neuroscience · 2024Article
- Enlarged cross-sectional area of the left vagus nerve in patients with major depressive disorder.Frontiers in psychiatry · 2023Article
- The pathophysiology and management of depression in cardiac surgery patients.Frontiers in psychiatry · 2023Review
- Treating depression in clinical practice: new insights on the multidisciplinary use of trazodone.Frontiers in psychiatry · 2023Review
- Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments.Brain, behavior, & immunity - health · 2022Review
- Noise Induced Depression-Like Behavior, Neuroinflammation and Synaptic Plasticity Impairments: The Protective Effects of Luteolin.Neurochemical research · 2022Article
- Pharmacological Treatment for Neuroinflammation in Stress-Related Disorder.Biomedicines · 2022Review
- Inflammatory processes linked to major depression and schizophrenic disorders and the effects of polypharmacy in psychiatry: evidence from a longitudinal study of 279 patients under therapy.European archives of psychiatry and clinical neuroscience · 2021Observational
- Expanding the drug discovery space with predicted metabolite-target interactions.Communications biology · 2021Article
- Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder.Frontiers in psychiatry · 2021Article
- Ketamine: The final frontier or another depressing end?Behavioural brain research · 2020Review
- Multimodal Psychotherapeutic Inpatient Therapy of Depression Is Successful in Patients With High Cytokine Production.Frontiers in psychiatry · 2020Article
- Is There an Association or Not?-Investigating the Association of Depressiveness, Physical Activity, Body Composition and Sleep With Mediators of Inflammation.Frontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence supports a mutual relationship between inflammation and major depression. A variety of mechanisms are outlined, indicating how inflammation may be involved in the pathogenesis, course and treatment of major depression. In particular, this review addresses 1) inflammatory cytokines as markers of depression and potential predictors of treatment response, 2) findings that cytokines interact with antidepressants and non-pharmacological antidepressive therapies, such as electroconvulsive therapy, deep brain stimulation and physical activity, 3) the influence of cytokines on the cytochrome (CYP) p450-system and drug efflux transporters, and 4) how cascades of inflammation might serve as antidepressant drug targets. A number of clinical trials have focused on agents with immunmodulatory properties in the treatment of depression, of which this review covers nonsteroidal anti-inflammatory drugs (NSAIDs), cytokine inhibitors, ketamine, polyunsaturated fatty acids, statins and curcumin. A perspective is also provided on possible future immune targets for antidepressant therapy, such as toll-like receptor-inhibitors, glycogen synthase kinase-3 inhibitors, oleanolic acid analogs and minocycline. Concluding from the available data, markers of inflammation may become relevant factors for more personalised planning and prediction of response of antidepressant treatment strategies. Agents with anti-inflammatory properties have the potential to serve as clinically relevant antidepressants. Further studies are required to better define and identify subgroups of patients responsive to inflammatory agents as well as to define optimal time points for treatment onset and duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.